Funded Grants

Back to results

Antipsychotic treatment in a genetic subtype of schizophrenia: Novel insights from neuroimaging and pharmacogenetics

Project Overview

Schizophrenia is a common and serious mental illness characterized by psychotic symptoms, social withdrawal and functional disabilities that are generally lifelong. Response to treatment with antipsychotics is variable and the manifestation of common side effects, including serious motor symptoms, is unpredictable. There is growing interest in the clinical and predictive value of using pharmacogenetic testing to determine a patient’s response to antipsychotic drugs. For this project, Dr. Butcher  will investigate the antipsychotic treatment response and functional and structural brain phenotypes in adults with 22q11.2 deletion syndrome (22q11.2DS), the only confirmed molecular genetic subtype of schizophrenia.

Principal Investigator

Nancy Butcher , University of Toronto

Partners and Donors

Bell Canada

Project Ongoing

Antipsychotic treatment in a genetic subtype of schizophrenia: Novel insights from neuroimaging and pharmacogenetics

  • Program Type

    Capacity building grants

  • Area of research

    Mental Health

  • Disease Area

    Mental illness

  • Competition

    Bell Mental Health Research Training Awards

  • Province

    Ontario

  • Start Date

    2013

  • Total Grant Amount

    $97,500

  • Health Canada Contribution

    $48,750